Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 1:164:105890.
doi: 10.1016/j.ejps.2021.105890. Epub 2021 Jun 1.

Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer

Affiliations
Review

Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer

Sunil Kumar Dubey et al. Eur J Pharm Sci. .

Abstract

Breast Cancer (BC) is a highly heterogeneous malignant carcinoma that is the most frequently occurring cancer in women. The major types of BC are luminal A, basal-like, luminal B, Human Epidermal Growth Factor Receptor 2 (HER2) positive/ Estrogen Receptor (ER) negative, and Triple-Negative BC (TNBC). The conventional therapies against BC include various chemotherapeutic agents in different combinations. Along with the chemotherapeutic drugs, alternatives like hormonal therapy, radiation, and nanotechnology are emerging fields in treating breast carcinoma. Dendrimers are three-dimensional hyperbranched nanosized structures that deal with the toxicity and resistance of chemotherapeutic agents in BC. These nanocarriers can carry drugs on the surface as well as inside the cavity to the desired site. Dendrimers have high loading capacity and exhibit targeted delivery of drugs resulting in reduced side effects. The current review discusses the utilization of dendrimers for treating BC and conquering the limitations of multidrug resistance.

Keywords: Breast cancer; Dendrimer; Drug delivery; Multidrug resistance; Nanotechnology.

PubMed Disclaimer

Similar articles

Cited by